Mariner’s Sonnet BioTherapeutics SONN Stock Holding History

Mariner’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-77	Closed	-$16K	–	2874
2022 Q4	$16K	Hold	77	–	–	﹤0.01%	2698
2022 Q3	$20K	Buy	+77	New	+$44.9K	﹤0.01%	2379

Other funds holding SONN

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mariner's SONN Position: Q1 2023 in Review

Mariner sold out of Sonnet BioTherapeutics (SONN) in Q1 2023, closing a stake of 77 shares — an estimated $16K sold.

Mariner first reported a position in SONN in Q3 2022 and held it in 2 quarters. The position peaked at $20K in Q3 2022. 16 funds tracked by Wall St. Rank hold SONN as of Q1 2023.

Mariner reported no remaining Sonnet BioTherapeutics position as of Q1 2023 after selling out during the quarter.
Mariner sold 77 Sonnet BioTherapeutics shares in Q1 2023, an estimated $16K.
Mariner first reported a position in Sonnet BioTherapeutics in Q3 2022 and held it in 2 quarters.
Mariner's Sonnet BioTherapeutics position peaked at $20K in Q3 2022.
16 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q1 2023.

Based on Mariner's 13F filing for Q1 2023, filed 15 May 2023.